Jump Financial LLC Acquires Shares of 103,826 Keros Therapeutics, Inc. $KROS

Key Points

• Jump Financial LLC acquired 103,826 shares of Keros Therapeutics, valuing their investment at approximately $1,058,000, representing 0.26% ownership in the company.
• Institutional investors continue to significantly increase their stakes in Keros Therapeutics, with notable increases from Braidwell LP and Federated Hermes, resulting in institutional ownership of 71.56% of the stock.
• Several brokerages have downgraded Keros Therapeutics' price targets, with the consensus rating currently a "Moderate Buy" and an average target price of $30.00.

Jump Financial LLC bought a new position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 103,826 shares of the company's stock, valued at approximately $1,058,000. Jump Financial LLC owned 0.26% of Keros Therapeutics as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of KROS. Braidwell LP raised its position in shares of Keros Therapeutics by 167.9% during the fourth quarter. Braidwell LP now owns 1,894,439 shares of the company's stock worth $29,989,000 after purchasing an additional 1,187,199 shares during the period. Federated Hermes Inc. grew its holdings in shares of Keros Therapeutics by 882.3% during the first quarter. Federated Hermes Inc. now owns 1,224,139 shares of the company's stock valued at $12,474,000 after buying an additional 1,099,519 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Keros Therapeutics by 31.1% during the first quarter. Vanguard Group Inc. now owns 2,566,321 shares of the company's stock valued at $26,151,000 after buying an additional 609,212 shares in the last quarter. Millennium Management LLC grew its holdings in shares of Keros Therapeutics by 53.3% during the fourth quarter. Millennium Management LLC now owns 878,159 shares of the company's stock valued at $13,901,000 after buying an additional 305,169 shares in the last quarter. Finally, Boxer Capital Management LLC purchased a new position in shares of Keros Therapeutics during the fourth quarter valued at $3,958,000. 71.56% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on KROS shares. Bank of America downgraded Keros Therapeutics from a "buy" rating to a "neutral" rating and lowered their price target for the company from $32.00 to $18.00 in a report on Tuesday, June 10th. Wedbush reiterated a "neutral" rating and set a $15.00 price target on shares of Keros Therapeutics in a report on Friday, May 30th. Scotiabank lowered their target price on Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating on the stock in a research note on Monday, May 12th. Finally, HC Wainwright lowered their target price on Keros Therapeutics from $25.00 to $20.00 and set a "buy" rating on the stock in a research note on Friday, August 8th. Seven research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $30.00.

Keros Therapeutics Stock Performance

Shares of KROS stock traded up $0.51 during trading hours on Tuesday, hitting $15.72. The company had a trading volume of 475,978 shares, compared to its average volume of 959,202. Keros Therapeutics, Inc. has a 12 month low of $9.12 and a 12 month high of $72.37. The firm has a market capitalization of $638.55 million, a price-to-earnings ratio of 50.71, a PEG ratio of 1.96 and a beta of 1.06. The firm's fifty day moving average is $14.22 and its 200 day moving average is $13.21.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.76) earnings per share for the quarter, beating the consensus estimate of ($1.14) by $0.38. Keros Therapeutics had a return on equity of 2.96% and a net margin of 8.06%.The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $3.83 million. During the same period in the prior year, the company posted ($1.25) EPS. The company's revenue was up 49002.7% compared to the same quarter last year. On average, sell-side analysts expect that Keros Therapeutics, Inc. will post -4.74 EPS for the current fiscal year.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.